Roivant Sciences Ltd. (NASDAQ:ROIV – Get Rating) has received a consensus rating of “Buy” from the nine research firms that are covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell rating and eight have given a buy rating to the company. The average 1 year target price among brokers that have issued ratings on the stock in the last year is $13.33.
ROIV has been the topic of several recent analyst reports. Zacks Investment Research lowered Roivant Sciences from a “hold” rating to a “sell” rating in a research report on Friday, February 18th. Cantor Fitzgerald assumed coverage on Roivant Sciences in a research report on Friday, April 29th. They set an “overweight” rating and a $15.00 price target on the stock.
In related news, CAO Rakhi Kumar sold 7,281 shares of the stock in a transaction that occurred on Friday, March 25th. The stock was sold at an average price of $5.06, for a total transaction of $36,841.86. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Matthew Gline sold 8,509 shares of the stock in a transaction that occurred on Monday, April 25th. The shares were sold at an average price of $3.84, for a total value of $32,674.56. Following the sale, the chief executive officer now owns 1,404,448 shares of the company’s stock, valued at approximately $5,393,080.32. The disclosure for this sale can be found here. In the last three months, insiders have sold 372,113 shares of company stock worth $1,902,993.
Shares of NASDAQ ROIV opened at $3.65 on Friday. Roivant Sciences has a 12 month low of $2.52 and a 12 month high of $16.76. The business has a fifty day simple moving average of $4.21 and a 200-day simple moving average of $6.71.
Roivant Sciences (NASDAQ:ROIV – Get Rating) last posted its quarterly earnings results on Monday, February 14th. The company reported ($0.41) earnings per share for the quarter, missing the consensus estimate of ($0.23) by ($0.18). The company had revenue of $24.34 million during the quarter, compared to analysts’ expectations of $10.13 million. On average, research analysts anticipate that Roivant Sciences will post -1.35 earnings per share for the current fiscal year.
Roivant Sciences Company Profile (Get Rating)
Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia.
- Get a free copy of the StockNews.com research report on Roivant Sciences (ROIV)
- Rapid7: Could Be Profitable in FY 2022 Despite Bear Market
- Will John Deere’s Earnings Help to Calm the Markets?
- Lowe’s Companies Has Not Bottomed
- Silicon Labs Stock is Falling to a Better Place
- The Institutional Tide Has Turned For Cisco Systems
Receive News & Ratings for Roivant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roivant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.